Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: A novel PDPN antagonist peptide CY12-RP2 inhibits melanoma growth via Wnt/β-catenin and modulates the immune cells

Fig. 5

Effects of CY12-RP2 on melanoma tumorigenesis in vivo. A Melanoma cell line A375 was subcutaneously implanted in BALB/c nude mice, and 5 days later treated with CY12-RP2 (25 mg/kg, 100 mg/kg) every two day for 15 days. Tumor mass was resected after the 15-day treatment period. B Tumor growth curve of subcutaneous melanoma xenograft. C The weight of orthotopic xenografts tumors at the end of the experiment. D Body weight of BALB/c nude mice over the course of the experiment. E Murine melanoma cell line B16F10-luc was subcutaneously implanted in BALB/c nude mice, and 5 days later treated with CY12-RP2 (25 mg/kg, 100 mg/kg) every two day for 15 days. Bioluminescence imaging of tumor growth in BALB/c mice was performed. F Statistical analysis of bioluminescence imaging. G The tumor volume after treating with CY12-RP2. H The body weight of mice after treating with CY12-RP2. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 versus control

Back to article page